ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

THE USE OF NINTEDANIB IN THE TREATMENT OF POST-COVID-19 FIBROSIS

Journal: International Journal of Advanced Research (Vol.10, No. 09)

Publication Date:

Authors : ; ;

Page : 64-68

Keywords : SARS-CoV-2 COVID-19 Pulmonary Fibrosis Anti-Fibrosis Nintedanib;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Pulmonary fibrosis is becoming a recognized complication of coronavirus disease 2019 (COVID-19). We report 2 cases of 2 patients aged 40 and 61 with pulmonary fibrosis due to COVID-19. The clinical examination showed that the 2 patients were dyspneic with a weak oxygen saturation and that there was bilateral crackles of the two pulmonary fields. High-resolution computed tomography showed bilateral multifocal ground glass opacities, subpleural fibrotic bands (between 25-50% and 75% parenchymal involvement). We prescribed them an anti-fibrosant, nintedanib, and there was a significant clinical and radiological improvement after 15 days of treatment. Nintedanib may have a new therapeutic role in the prevention of fibrosis associated with COVID-19.

Last modified: 2022-10-04 19:20:44